Hereditary Pancreatic Cancer Syndromes

Surgical Oncology Clinics of North America

Volumn 24, Issue 4, 2015, Pages 733-764

  Connor, Ashton A ^a   Gallinger, Steven ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adenocarcinoma; Cancer; Exocrine; Familial; Genetics; Hereditary; Pancreas; Syndrome

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUOROURACIL; GEMCITABINE; MISMATCH REPAIR PROTEIN; PROTEIN KINASE LKB1;

ALCOHOL ABUSE; APC GENE; ATAXIA TELANGIECTASIA; ATM GENE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CDKN2A GENE; CFTR GENE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIET; DISEASE ASSOCIATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILIAL PANCREATIC CANCER; FAMILY HISTORY; FIRST DEGREE RELATIVE; GENE; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY PANCREATIC CANCER SYNDROME; HETEROZYGOTE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; METASTASIS; MMR GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ONSET AGE; OVERALL SURVIVAL; PALB2 GENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PANCREATITIS; PENETRANCE; PEUTZ JEGHERS SYNDROME; PRSS1 GENE; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT ALLERGY; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPINK1 GENE; STK11 GENE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; DISEASE MANAGEMENT; GENETIC PREDISPOSITION; GENETICS; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; RISK ASSESSMENT;

DISEASE MANAGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84941260158     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2015.06.007     Document Type: Review

References (238)

1. Rahib L., Smith B.D., Aizenberg R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74(11):2913-2921. [Erratum appears in Cancer Res 2014;74(14):4006].
2. Nishihara R., Wu K., Lochhead P., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013, 369(12):1095-1105.
3. US Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151(10):716-726. W-236. [Erratum appears in Ann Intern Med 2010;152(10):688; and Erratum appears in Ann Intern Med 2010;152(3):199-200].
4. National Lung Screening Trial Research Team, Church T.R., Black W.C., et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013, 368(21):1980-1991.
5. de Koning H.J., Meza R., Plevritis S.K., et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014, 160(5):311-320.
6. Jenkins M.A., Dowty J.G., Ait Ouakrim D., et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. J Clin Oncol 2015, 33(4):326-331.
7. Becker A.E., Hernandez Y.G., Frucht H., et al. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 2014, 20(32):11182-11198.
8. Roberts N.J., Klein A.P. Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Cancer Lett 2013, 340(2):227-233.
9. Arends M.J. Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol 2013, 21(2):97-102.
10. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349(3):247-257.
11. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29. [Erratum appears in CA Cancer J Clin 2014;64(5):364].
12. Kanji Z.S., Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ 2013, 185(14):1219-1226.
13. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014, 371(11):1039-1049.
14. Yachida S., Jones S., Bozic I., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467(7319):1114-1117.
15. Haeno H., Gonen M., Davis M.B., et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012, 148(1-2):362-375.
16. Rhim A.D., Mirek E.T., Aiello N.M., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148(1-2):349-361.
17. Saif M.W. Advanced stage pancreatic cancer: novel therapeutic options. Expert Rev Clin Pharmacol 2014, 7(4):487-498.
18. McIntyre C.A., Winter J.M. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015, 42(1):19-27.
19. AJCC cancer staging manual 2010, Springer, New York. 7th edition. S. Edge, D.R. Byrd, C.C. Compton (Eds.).
20. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27(11):1806-1813.
21. Donahue T.R., Reber H.A. Surgical management of pancreatic cancer-pancreaticoduodenectomy. Semin Oncol 2015, 42(1):98-109.
22. Parikh P.Y., Lillemoe K.D. Surgical management of pancreatic cancer-distal pancreatectomy. Semin Oncol 2015, 42(1):110-122.
23. Li D., O'Reilly E.M. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015, 42(1):134-143.
24. Winner M., Goff S.L., Chabot J.A. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Semin Oncol 2015, 42(1):86-97.
25. Gooiker G.A., van Gijn W., Wouters M.W., Signalling Committee Cancer of the Dutch Cancer Society, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011, 98(4):485-494.
26. Conroy T., Desseigne F., Ychou M., Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
27. Papadatos-Pastos D., Thillai K., Rabbie R., et al. FOLFIRINOX-a new paradigm in the treatment of pancreatic cancer. Expert Rev Anticancer Ther 2014, 14(10):1115-1125.
28. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703.
29. Moore M.J., Goldstein D., Hamm J., National Cancer Institute of Canada Clinical Trials Group, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
30. Chuong M.D., Boggs D.H., Patel K.N., et al. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?. J Gastrointest Oncol 2014, 5(3):166-177.
31. Bosetti C., Lucenteforte E., Silverman D.T., et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012, 23(7):1880-1888. [Erratum appears in Ann Oncol 2012;23(10):2773].
32. Lynch S.M., Vrieling A., Lubin J.H. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009, 170(4):403-413.
33. Villeneuve P.J., Johnson K.C., Mao Y., Canadian Cancer Registries Research Group, et al. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health 2004, 95(1):32-37.
34. Bertuccio P., La Vecchia C., Silverman D.T. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2011, 22(6):1420-1426.
35. Bosetti C., Rosato V., Li D. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 2014, 25(10):2065-2072.
36. Elena J.W., Steplowski E., Yu K. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 2013, 24(1):13-25.
37. Duell E.J., Lucenteforte E., Olson S.H. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012, 23(11):2964-2970.
38. Lucenteforte E., La Vecchia C., Silverman D., et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012, 23(2):374-382.
39. Michaud D.S., Vrieling A., Jiao L., et al. Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes Control 2010, 21(8):1213-1225.
40. Arslan A.A., Helzlsouer K.J., Kooperberg C., et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010, 170(9):791-802. Pancreatic Cancer Cohort Consortium (PanScan).
41. Larsson S.C., Orsini N., Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 2007, 120(9):1993-1998.
42. Bosetti C., Lucenteforte E., Bracci P.M., et al. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2013, 24(11):2903-290
43. Cotterchio M., Lowcock E., Hudson T.J., et al. Association between allergies and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2014, 23(3):469-480.
44. Olson S.H., Hsu M., Satagopan J.M., et al. Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Am J Epidemiol 2013, 178(5):691-700. Pancreatic Cancer Case-Control Consortium.
45. Humphris J.L., Johns A.L., Simpson S.H., Australian Pancreatic Cancer Genome Initiative, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer 2014, 120(23):3669-3675.
46. Klein A.P., Beaty T.H., Bailey-Wilson J.E., et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23(2):133-149.
47. Amundadottir L., Kraft P., Stolzenberg-Solomon R.Z., et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009, 41(9):986-990.
48. Petersen G.M., Amundadottir L., Fuchs C.S., et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010, 42(3):224-228.
49. Diergaarde B., Brand R., Lamb J., et al. Pooling-based genome-wide association study implicates gamma-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology 2010, 10(2-3):194-200.
50. Low S.K., Kuchiba A., Zembutsu H., et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS One 2010, 5(7):e11824.
51. Wu C., Miao X., Huang L., et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet 2011, 44(1):62-66.
52. Willis J.A., Olson S.H., Orlow I., et al. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res 2012, 18(14):3942-3951.
53. Wu C., Kraft P., Stolzenberg-Solomon R., et al. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut 2014, 63(1):152-160.
54. Wolpin B.M., Rizzato C., Kraft P., et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet 2014, 46(9):994-1000.
55. Wolpin B.M., Kraft P., Gross M., et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010, 70(3):1015-1023.
56. Wolpin B.M., Kraft P., Xu M., et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 2010, 19(12):3140-3149.
57. Greer J.B., LaRusch J., Brand R.E., NAPS2 Study Group, et al. ABO blood group and chronic pancreatitis risk in the NAPS2 cohort. Pancreas 2011, 40(8):1188-1194.
58. Lin Y., Yagyu K., Egawa N., et al. An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies. J Epidemiol 2011, 21(1):2-12.
59. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system 2010, WHO Press, Geneva (Switzerland). 4th edition. F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.).
60. Rishi A., Goggins M., Wood L.D., et al. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol 2015, 42(1):28-39.
61. AJCC cancer staging manual 2009, Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, M.A. Carducci (Eds.).
62. AJCC cancer staging Atlas 2012, Springer, New York. C.C. Compton, D.R. Byrd, J. Garcia-Aguilar (Eds.).
63. Adsay N.V., Basturk O., Bonnett M., et al. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol 2005, 29(6):724-733.
64. Giulianotti P.C., Boggi U., Fornaciari G., et al. Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Klöppel vs TNM grading. Int J Pancreatol 1995, 17(3):279-289.
65. Wasif N., Ko C.Y., Farrell J., et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging?. Ann Surg Oncol 2010, 17(9):2312-2320.
66. Rochefort M.M., Ankeny J.S., Kadera B.E., et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol 2013, 20(13):4322-4329.
67. Lim J.E., Chien M.W., Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003, 237(1):74-85.
68. Park H., An S., Eo S.H., et al. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Hum Pathol 2014, 45(11):2341-2346.
69. Matsumoto G., Muta M., Tsuruta K., et al. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer. Pancreatology 2007, 7(2-3):167-173.
70. Moon H.J., An J.Y., Heo J.S., et al. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 2006, 32(1):37-43.
71. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993, 165(1):68-72. [discussion: 72-3].
72. Garcea G., Dennison A.R., Ong S.L., et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007, 33(7):892-897.
73. House M.G., Gönen M., Jarnagin W.R., et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007, 11(11):1549-1555.
74. Pawlik T.M., Gleisner A.L., Cameron J.L., et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141(5):610-618.
75. Riediger H., Keck T., Wellner U., et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009, 13(7):1337-1344.
76. Dusch N., Weiss C., Ströbel P., et al. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 2014, 18(4):674-681.
77. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001, 25(5):579-586.
78. Hruban R.H., Goggins M., Parsons J., et al. Progression model for pancreatic cancer. Clin Cancer Res 2000, 6(8):2969-2972.
79. Shi C., Klein A.P., Goggins M., et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009, 15:7737-7743.
80. Lowery M.A., Kelsen D.P., Stadler Z.K., et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011, 16(10):1397-1402.
81. Lowery M.A., Klimstra D.S., Shia J., et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist 2011, 16(12):1714-1720.
82. Banville N., Geraghty R., Fox E., et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol 2006, 37(11):1498-1502.
83. Goggins M., Offerhaus G.J., Hilgers W., et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998, 152(6):1501-1507.
84. Wilentz R.E., Goggins M., Redston M., et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol 2000, 156(5):1641-1651.
85. Denost Q., Chafai N., Arrive L., et al. Hereditary intraductal papillary mucinous neoplasm of the pancreas. Clin Res Hepatol Gastroenterol 2012, 36(2):e23-e25.
86. Sato N., Rosty C., Jansen M., et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001, 159(6):2017-2022.
87. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4(6):766-781. [quiz: 665].
88. Maire F., Hammel P., Terris B., et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 2002, 51(3):446-449.
89. Chetty R., Salahshor S., Bapat B., et al. Intraductal papillary mucinous neoplasm of the pancreas in a patient with attenuated familial adenomatous polyposis. J Clin Pathol 2005, 58(1):97-101.
90. Chetty R., Serra S., Salahshor S., et al. Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. Hum Pathol 2006, 37(2):212-217.
91. Wu J., Matthaei H., Maitra A., et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011, 3(92):92ra66.
92. Furukawa T., Kuboki Y., Tanji E., et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011, 1:161.
93. Takano S., Fukasawa M., Maekawa S., et al. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One 2014, 9(6):e98718.
94. Amato E., Molin M.D., Mafficini A., et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014, 233(3):217-227.
95. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64(7):2634-2638.
96. Bartsch D.K., Kress R., Sina-Frey M., et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004, 110(6):902-906.
97. Hemminki K., Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003, 103(4):525-530.
98. Permuth-Wey J., Egan K.M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009, 8(2):109-117.
99. Tomasetti C., Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015, 347(6217):78-81.
100. Fernandez E., La Vecchia C., D'Avanzo B., et al. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994, 3(3):209-212.
101. Grant R.C., Selander I., Connor A.A., et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2015, 148(3):556-564.
102. Holter S., Borgida A., Dodd A., et al. BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol 2015, [Epub ahead of print].
103. Risch H.A., McLaughlin J.R., Cole D.E., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006, 98(23):1694-1706.
104. Rahman N., Seal S., Thompson D., et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39(2):165-167. Breast Cancer Susceptibility Collaboration (UK).
105. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000, 83(10):1301-1308.
106. Whittemore A.S., Gong G., John E.M., et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004, 13(12):2078-2083.
107. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336(20):1401-1408.
108. King M.C., Marks J.H., Mandell J.B., New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-646.
109. John E.M., Miron A., Gong G., et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007, 298(24):2869-2876.
110. Struewing J.P., Abeliovich D., Peretz T., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995, 11(2):198-200. [Erratum appears in Nat Genet 1996;12(1):110].
111. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14(2):185-187.
112. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62(13):3789-3793.
113. Hahn S.A., Greenhalf B., Ellis I., et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003, 95(3):214-221.
114. Couch F.J., Johnson M.R., Rabe K.G., et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(2):342-346.
115. Goggins M., Schutte M., Lu J., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56(23):5360-5364.
116. Lucas A.L., Shakya R., Lipsyc M.D., et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013, 19(13):3396-3403.
117. Ferrone C.R., Levine D.A., Tang L.H., et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009, 27(3):433-438.
118. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002, 94(18):1365-1372.
119. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94(18):1358-1365. Breast Cancer Linkage Consortium.
120. Axilbund J.E., Argani P., Kamiyama M., et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther 2009, 8(2):131-135.
121. Moran A., O'Hara C., Khan S., et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012, 11(2):235-242.
122. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91(15):1310-1316. Breast Cancer Linkage Consortium.
123. Mersch J., Jackson M.A., Park M., et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015, 121(2):269-275.
124. Iqbal J., Ragone A., Lubinski J., Hereditary Breast Cancer Study Group, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012, 107(12):2005-2009.
125. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005, 42(9):711-719. Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON).
126. Kim D.H., Crawford B., Ziegler J., et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer 2009, 8(2):153-158.
127. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324(5924):217.
128. Slater E.P., Langer P., Niemczyk E., et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010, 78(5):490-494.
129. Tischkowitz M.D., Sabbaghian N., Hamel N., et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009, 137(3):1183-1186.
130. Schneider R., Slater E.P., Sina M., et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011, 10(2):323-330.
131. Harinck F., Kluijt I., van Mil S.E., et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 2012, 20(5):577-579.
132. Casadei S., Norquist B.M., Walsh T., et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011, 71(6):2222-2229.
133. Rogers C.D., Couch F.J., Brune K., et al. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004, 41(12):e126.
134. van der Heijden M.S., Yeo C.J., Hruban R.H., et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63(10):2585-2588.
135. Rogers C.D., van der Heijden M.S., Brune K., et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004, 3(2):167-169.
136. Couch F.J., Johnson M.R., Rabe K., et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005, 65(2):383-386.
137. Lynch H.T., Snyder C.L., Shaw T.G., et al. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 2015, 15(3):181-194.
138. Kuiper R.P., Vissers L.E., Venkatachalam R., et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011, 32(4):407-414.
139. Al-Sukhni W., Aronson M., Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and Lynch syndrome. Surg Clin North Am 2008, 88(4):819-844. vii.
140. Talseth-Palmer B.A., Wijnen J.T., Grice D.M., et al. Genetic modifiers of cancer risk in Lynch syndrome: a review. Fam Cancer 2013, 12(2):207-216.
141. Chen S., Wang W., Lee S., Colon Cancer Family Registry, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006, 296(12):1479-1487.
142. Laitman Y., Herskovitz L., Golan T., et al. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. Fam Cancer 2012, 11(2):243-247.
143. Gargiulo S., Torrini M., Ollila S., et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer 2009, 8(4):547-553.
144. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302(16):1790-1795.
145. Geary J., Sasieni P., Houlston R., et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 2008, 7(2):163-172.
146. Neklason D.W., Stevens J., Boucher K.M., et al. American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008, 6(1):46-52.
147. Green R.C., Green J.S., Buehler S.K., et al. Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies. Fam Cancer 2007, 6(1):53-62.
148. Giardiello F.M., Offerhaus G.J., Lee D.H., et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34(10):1394-1396.
149. Korsse S.E., Peppelenbosch M.P., van Veelen W. Targeting LKB1 signaling in cancer. Biochim Biophys Acta 2013, 1835(2):194-210.
150. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119(6):1447-1453.
151. van Lier M.G., Wagner A., Mathus-Vliegen E.M., et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010, 105(6):1258-1264. [author reply: 1265].
152. Olschwang S., Boisson C., Thomas G. Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma. J Med Genet 2001, 38(6):356-360.
153. Foulkes W.D., Flanders T.Y., Pollock P.M., et al. The CDKN2A (p16) gene and human cancer. Mol Med 1997, 3(1):5-20.
154. Aoude L.G., Wadt K.A., Pritchard A.L., et al. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 2015, 28(2):148-160.
155. Vasen H.F., Gruis N.A., Frants R.R., et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000, 87(6):809-811.
156. Goldstein A.M., Struewing J.P., Chidambaram A., et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000, 92(12):1006-1010.
157. Lynch H.T., Brand R.E., Hogg D., et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002, 94(1):84-96.
158. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006, 66(20):9818-9828. Melanoma Genetics Consortium (GenoMEL).
159. Borg A., Sandberg T., Nilsson K., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92(15):1260-1266.
160. Goldstein A.M., Fraser M.C., Struewing J.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995, 333(15):970-974.
161. Bartsch D.K., Sina-Frey M., Lang S., et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002, 236(6):730-737.
162. McWilliams R.R., Wieben E.D., Rabe K.G., et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet 2011, 19(4):472-478.
163. LaRusch J., Whitcomb D.C. Genetics of pancreatitis. Curr Opin Gastroenterol 2011, 27(5):467-474.
164. Witt H., Luck W., Hennies H.C., et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000, 25(2):213-216.
165. Aoun E., Chang C.C., Greer J.B., et al. Pathways to injury in chronic pancreatitis: decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. PLoS One 2008, 3(4):e2003.
166. de las Heras-Castaño G., Castro-Senosiaín B., Fontalba A., et al. Hereditary pancreatitis: clinical features and inheritance characteristics of the R122C mutation in the cationic trypsinogen gene (PRSS1) in six Spanish families. JOP 2009, 10(3):249-255.
167. Rebours V., Boutron-Ruault M.C., Schnee M., et al. The natural history of hereditary pancreatitis: a national series. Gut 2009, 58(1):97-103.
168. Raimondi S., Lowenfels A.B., Morselli-Labate A.M., et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010, 24(3):349-358.
169. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89(6):442-446.
170. Lowenfels A.B., Maisonneuve P., Whitcomb D.C., et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001, 286(2):169-170.
171. Guillot L., Beucher J., Tabary O., et al. Lung disease modifier genes in cystic fibrosis. Int J Biochem Cell Biol 2014, 52:83-93.
172. Sosnay P.R., Siklosi K.R., Van Goor F., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013, 45(10):1160-1167.
173. Hamosh A., FitzSimmons S.C., Macek M., et al. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998, 132(2):255-259.
174. Kerem B., Chiba-Falek O., Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997, 1(1):35-39.
175. Maisonneuve P., Marshall B.C., Lowenfels A.B. Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007, 56(9):1327-1328.
176. McWilliams R.R., Petersen G.M., Rabe K.G., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2010, 116(1):203-209.
177. Matsubayashi H., Fukushima N., Sato N., et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther 2003, 2(6):652-655.
178. Mavrou A., Tsangaris G.T., Roma E., et al. The ATM gene and ataxia telangiectasia. Anticancer Res 2008, 28(1B):401-405.
179. Goldgar D.E., Healey S., Dowty J.G., BCFR, kConFab, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011, 13(4):R73.
180. Taylor A.M., Byrd P.J. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005, 58(10):1009-1015.
181. Roberts N.J., Jiao Y., Yu J., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012, 2(1):41-46.
182. Swift M., Sholman L., Perry M., et al. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976, 36(1):209-215.
183. Swift M., Reitnauer P.J., Morrell D., et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987, 316(21):1289-1294.
184. Geoffroy-Perez B., Janin N., Ossian K., et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001, 93(2):288-293.
185. Rulyak S.J., Lowenfels A.B., Maisonneuve P., et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124(5):1292-1299.
186. Barton J.G., Schnelldorfer T., Lohse C.M., et al. Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. J Gastrointest Surg 2011, 15(5):836-842.
187. McFaul C.D., Greenhalf W., Earl J., European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC), German National Case Collection for Familial Pancreatic Cancer (FaPaCa), et al. Anticipation in familial pancreatic cancer. Gut 2006, 55(2):252-258.
188. Eberle M.A., Pfützer R., Pogue-Geile K.L., et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 2002, 70(4):1044-1048.
189. Pogue-Geile K.L., Chen R., Bronner M.P., et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3(12):e516.
190. Earl J., Yan L., Vitone L.J., European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, German National Case Collection for Familial Pancreatic Cancer, et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1948-1955.
191. Klein A.P., Borges M., Griffith M., et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1328-1330.
192. Slater E., Amrillaeva V., Fendrich V., et al. Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 2007, 4(4):e164.
193. Lieberman M.D., Kilburn H., Lindsey M., et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995, 222(5):638-645.
194. Raval M.V., Bilimoria K.Y., Talamonti M.S. Quality improvement for pancreatic cancer care: is regionalization a feasible and effective mechanism?. Surg Oncol Clin N Am 2010, 19(2):371-390.
195. Hampel H., Bennett R.L., Buchanan A., Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 2015, 17(1):70-87.
196. Ozçelik H., Schmocker B., Di Nicola N., et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16(1):17-18.
197. Wang W., Chen S., Brune K.A., et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007, 25(11):1417-1422.
198. LaDuca H., Stuenkel A.J., Dolinsky J.S., et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014, 16(11):830-837.
199. Landrum M.J., Lee J.M., Riley G.R., et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014, 42(Database issue):D980-D985.
200. Thompson B.A., Spurdle A.B., Plazzer J.P., InSiGHT, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 2014, 46(2):107-115.
201. Rulyak S.J., Brentnall T.A. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001, 1(5):477-485.
202. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2(7):606-621.
203. Poley J.W., Kluijt I., Gouma D.J., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009, 104(9):2175-2181.
204. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58(10):1410-1418.
205. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16(20):5028-5037.
206. Ludwig E., Olson S.H., Bayuga S., et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011, 106(5):946-954.
207. Canto M.I., Hruban R.H., Fishman E.K., et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012, 142(4):796-804. American Cancer of the Pancreas Screening (CAPS) Consortium, [quiz: e14-5].
208. Al-Sukhni W., Borgida A., Rothenmund H., et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012, 16(4):771-783.
209. Canto M.I., Harinck F., Hruban R.H., et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013, 62(3):339-347. International Cancer of Pancreas Screening (CAPS) Consortium, [Erratum appears in Gut 2014;63(12):1978]. Hammell, Pascal [corrected to Hammel, Pascal]. Gut 2014;63(1):178. Hamell, Pascal [corrected to Hammell, Pascal].
210. Fong Z.V., Winter J.M. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J 2012, 18(6):530-538.
211. Ballehaninna U.K., Chamberlain R.S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012, 3(2):105-119.
212. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006, 30(9):1067-1076.
213. Rulyak S.J., Kimmey M.B., Veenstra D.L., et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57(1):23-29.
214. Rubenstein J.H., Scheiman J.M., Anderson M.A. A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma. Pancreatology 2007, 7(5-6):514-525.
215. Rhim A.D., Thege F.I., Santana S.M., et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 2014, 146(3):647-651.
216. Bellin M.D., Freeman M.L., Gelrud A., PancreasFest Recommendation Conference Participants, et al. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology 2014, 14(1):27-35.
217. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355(13):1318-1330.
218. Mills P.K., Beeson W.L., Abbey D.E., et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988, 61(12):2578-2585.
219. Skinner H.G., Michaud D.S., Giovannucci E., et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 2006, 15(9):1688-1695.
220. Nöthlings U., Wilkens L.R., Murphy S.P., et al. Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 2005, 97(19):1458-1465. [Erratum appears in J Natl Cancer Inst 2006;98(11):796].
221. Waddell N., Pajic M., Patch A.M., Australian Pancreatic Cancer Genome Initiative, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518(7540):495-501.
222. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Australian Pancreatic Cancer Genome Initiative, ICGC PedBrain, et al. Signatures of mutational processes in human cancer. Nature 2013, 500(7463):415-421. ICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, [Erratum appears in Nature 2013;502(7470):258]. Imielinsk, Marcin [corrected to Imielinski, Marcin].
223. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
224. Tutt A.N., Lord C.J., McCabe N., et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005, 70:139-148.
225. Pennington K.P., Walsh T., Harrell M.I., et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014, 20(3):764-775.
226. Ko A.H., Dito E., Schillinger B., et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006, 24(3):379-385.
227. Hess V., Pratsch S., Potthast S., et al. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 2010, 21(12):2390-2395.
228. Oettle H., Riess H., Stieler J.M., et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014, 32(23):2423-2429.
229. Sultana A., Smith C.T., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007, 25(18):2607-2615.
230. Sultana A., Tudur Smith C., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008, 99(1):6-13.
231. Ciliberto D., Botta C., Correale P., et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013, 49(3):593-603.
232. Heinemann V., Boeck S., Hinke A., et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82.
233. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011, 10(1):3-8.
234. Sonnenblick A., Kadouri L., Appelbaum L., et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 2011, 12(3):165-168.
235. Golan T., Kanji Z.S., Epelbaum R., et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014, 111(6):1132-1138.
236. US National Institutes of Health. Olaparib in gBRCA mutated pancreatic cancer who disease has not progressed on first line platinum-based chemotherapy (POLO). Available at: http://clinicaltrials.gov/show/NCT02184195.
237. Fogelman D.R., Wolff R.A., Kopetz S., et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011, 31(4):1417-1420.
238. Guillotin D., Martin S.A. Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp Cell Res 2014, 329(1):110-115.